Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PLB1004
i
Other names:
PLB1004
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Avistone Biotech
Drug class:
EGFR inhibitor
Related drugs:
‹
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
cetuximab (347)
osimertinib (301)
erlotinib (235)
afatinib (227)
gefitinib (194)
panitumumab (123)
lapatinib (107)
neratinib (102)
pyrotinib (79)
brigatinib (50)
icotinib (45)
aumolertinib (39)
amivantamab-vmjw (25)
firmonertinib (14)
mobocertinib (12)
lazertinib (12)
BGB-283 (12)
tarloxotinib bromide (7)
WZ4002 (7)
CH7233163 (6)
H002 (6)
nimotuzumab (6)
BLU-945 (6)
ASLAN001 (6)
BBT-176 (5)
CL-387785 (5)
GB263T (5)
rociletinib (5)
BDTX-189 (5)
AEE788 (4)
BDTX-1535 (4)
BI-4020 (4)
tomuzotuximab (4)
JIN-A02 (4)
TAS2940 (4)
VRN11 (4)
MET306 (4)
EGF816 (4)
AFM24 (3)
BLU-701 (3)
GC-1118A (3)
MCLA-129 (3)
necitumumab (3)
befotertinib (3)
BCA101 (3)
S95026 (3)
ASP8273 (3)
DZD9008 (3)
SZMD4 (3)
AZD3759 (3)
ACE2016 (2)
BI-732 (2)
BLU-451 (2)
Bay846 (2)
ERAS-801 (2)
OBX02-011 (2)
olmutinib (2)
QL1203 (2)
CLN-081 (2)
14aj (1)
ABN202 (1)
ABP 494 (cetuximab biosimilar) (1)
APL-103 (1)
BAY 2927088 (1)
BPI-15086 (1)
BPI-361175 (1)
Compound 6a (1)
abivertinib (1)
KKI04 (1)
PH001 (1)
rilertinib (1)
TAS3351 (1)
TRX-221 (1)
WSD0922 (1)
JMT101 (1)
S-222611 (1)
HMPL-813 (1)
SI-B001 (1)
ASK120067 (1)
HLX07 (1)
Hemay022 (1)
KD019 (1)
ABT-101 (0)
AC480 (0)
AG1478 (0)
BBT-207 (0)
BC3448 (0)
BMS690514 (0)
CM93 (0)
CUDC-101 (0)
EGF-PTI (0)
DF9001 (0)
DK210 (0)
STI-001 (cetuximab biosimilar) (0)
FHND9041 (0)
HLX35 (0)
HS-10375 (0)
antroquinonol (0)
zalutumumab (0)
IAE0972 (0)
IBI-334 (0)
JANX008 (0)
JNJ-26483327 (0)
JS111 (0)
MM-151 (0)
MP412 (0)
MTX-211 (0)
PF-08046052 (0)
PM1080 (0)
QLH11811 (0)
rindopepimut (0)
SR13668 (0)
SYN004 (0)
Sym013 (0)
TAK-186 (0)
TAK-285 (0)
TAS-121 (0)
TAVO412 (0)
THE-349 (0)
TQ-B3456 (0)
TQB3804 (0)
U3-1565 (0)
Undisclosed EGFR inhibitor (0)
XZP-5809 (0)
simotinib (0)
ZN-e4 (0)
AST1306 (0)
SY101 (0)
Ami-LC (0)
TY-9591 (0)
EMB-01 (0)
cetuximab biosimilar (0)
cipatinib (0)
ABT-806 (0)
MEHD7945A (0)
RO5083945 (0)
TL007 (0)
EMD 72000 (0)
PF-06747775 (0)
JNJ-64041757 (0)
KBP-5209 (0)
SKLB-1028 (0)
AZD8931 (0)
›
Associations
News
Trials
Filter by
Latest
7d
Kannon: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR Ex20ins Mutation Patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
P2, N=157, Recruiting, Avistone Biotechnology Co., Ltd. | Trial primary completion date: Apr 2024 --> Oct 2024
7 days ago
Trial primary completion date • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
PLB1004
3ms
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. (clinicaltrials.gov)
P2, N=120, Recruiting, Avistone Biotechnology Co., Ltd.
3 months ago
New P2 trial • Metastases
|
Tagrisso (osimertinib) • bozitinib (APL-101) • PLB1004
4ms
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=81, Recruiting, Avistone Biotechnology Co., Ltd. | Active, not recruiting --> Recruiting | Initiation date: Nov 2023 --> Jul 2024
4 months ago
Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
PLB1004
8ms
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI (clinicaltrials.gov)
P1/2, N=156, Recruiting, Avistone Biotechnology Co., Ltd.
8 months ago
New P1/2 trial
|
bozitinib (APL-101) • PLB1004
9ms
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. (clinicaltrials.gov)
P3, N=327, Not yet recruiting, Avistone Biotechnology Co., Ltd.
9 months ago
New P3 trial
|
EGFR (Epidermal growth factor receptor)
|
cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • PLB1004
11ms
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=82, Active, not recruiting, Avistone Biotechnology Co., Ltd. | Not yet recruiting --> Active, not recruiting
11 months ago
Enrollment closed
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
PLB1004
1year
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=82, Not yet recruiting, Avistone Biotechnology Co., Ltd.
1 year ago
New P1 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
PLB1004
1year
Kannon: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
P2, N=157, Recruiting, Avistone Biotechnology Co., Ltd.
1 year ago
New P2 trial • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
PLB1004
1year
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P1, N=91, Active, not recruiting, Avistone Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Nov 2024 | Trial primary completion date: May 2022 --> Apr 2023
1 year ago
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation
|
PLB1004
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login